SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Pulmonary, Allergy and Critical Care Medicine



[Return To Index page]
photo Rama K. Mallampalli, MD

Division Chief, Division of Pulmonary, Allergy and Critical Care Medicine

UPMC Endowed Professor and Director, Acute Lung Injury Center of Excellence

Email: mallampallirk@upmc.edu

Phone: 412-624-7441

Contact
Office: UPMC Montefiore Hospital, NW628
3459 Fifth Avenue
Pittsburgh, PA 15213
 
Phone: 412-624-7441
Fax: 412-624-1670
E-mail: mallampallirk@upmc.edu
Administrative Assistant:
Kelly Hall
Email: hallkl2@upmc.edu
Phone: 412-624-7441
Fax: 412-624-1670
Administrative Assistant:
Mary Pat Rocco
Email: roccomp@upmc.edu
Phone: 412-624-8735
Education and Training
Education
BS, Biology and Chemistry, Northland College, Wisconsin, 1980
MD, University of Wisconsin Medical School, 1984
Training
Residency, Internal Medicine, Hennepin County Medical Center, Minnesota, 1987
Chief Resident, Internal Medicine, Hennepin County Medical Center, Minnesota, 1988
Fellowship, Pulmonary Diseases and Critical Care, University of Iowa Hospitals and Clinics, 1991
Research Interest
Dr. Mallampalli’s research in the area of pulmonary molecular and cell biology as it relates to acute lung injury (ALI) and the mechanisms of sepsis. He is an internationally recognized investigator in the area of lipid metabolism and ubiquitin-mediated proteolysis as it relates to inflammation and injury. His research program discovered a unique model for the molecular behavior of ubiquitin E3 ligase subunits that control inflammation. Dr. Mallampalli’s laboratory designed, synthesized, and tested the first-in-class genus of ubiquitin E3 ligase (F box) inhibitors that modulate proteolysis thereby inhibiting inflammation in preclinical models of ALI and multi-organ failure. He currently leads an NIH Program Project grant in ALI and a Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage II (CADETII) award to develop drug therapies for inflammatory lung illness.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Bednash, J, Weathington, N, Londino, JD, Rojas, M, Han, S, Gullick, D, Fort, R, McKelvey, AC, Chen, BB, Mallampalli, RK. Targeting of the Deubiquitinase STAMBP. Nat Commun. 2017; In Press.
Liu, Y, Lear, T, Iannone, O, Siva, S, Corey, C, Rajbhandari, S, Jerome, J, Chen, BB, Mallampalli, RK. Pro-apoptotic F-box protein Fbxl7 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin. J Biol. Chem. 2015; May 8;290: 11843-52.
Chen, W, Xiong, S, Li, J, Li, X, Liu, Y, Zou, C, Mallampalli, RK. The ubiquitin E3 ligase SCF-FBXO24 recognizes acetylated nucleoside diphosphate kinase A to regulate its degradation. Mol. Cell Biol. 2015; 35(6): 1001-13.
Zou, C, Li, J, Chen, W, Chen, Y, Xiong, S, Snavely, C, Chen, BB, Mallampalli, RK. Morf4l1 mediates apoptosis in experimental pneumonia. Science Transl. Med. 2015; In Press.
Chen, BB, Coon, TA, Glasser, JR, Zou, C, Ellis, B, Das, T, McKelvey, AC, Rajbhandari, S, Lear, T, Kamga, C, Shiva, S, Li, C, Pilewski, JM, Callio, J, Chu, CT, Ray, A, Ray, P, Tyurina, YY, Kagen, VE, Mallampalli, RK. E3 ligase subunit Fbxo15 and PINK1 kinase regulate cardiolipin synthase 1 stability and mitochondrial function in pneumonia. Cell Rep. 2014; 7(2): 476-87.
Weathington, NM, Mallampalli, RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014; Jan 124(1): 6-12.
Han, S, Mallampalli, RK. Sizing up surfactant synthesis. Cell Metab. 2014; 20: 195-196.
Chen, BB, Coon, TA, Glasser, JR, McVerry, MB, Zhao, J, Zhao, Y, Zou, C, Ellis, B, Sciurba, FC, Zhang, Y, Mallampalli, RK. A combinatorial F box protein directed pathway controls TRAF stability to regulate inflammation. Nat Immunol. 2013; May; 14(5): 470-9.
Zhao, J, Wei, J, Mialki, RK, Mallampalli, DF, Chen, BB, Coon, TA, Zou, C, Mallampalli, RK, Zhao, Y. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nature Immunol. 2012; June 3;13(7): 651-8.
Ray, NB, Durairaj, L, Chen, BB, McVerry, BJ, Ryan, AJ, Donahoe, M, Waltenbough, AK, O'Donnell, CP, Henderson, FC, Etscheidt, CA, McCoy, DM, Agassandian, M, Hayes-Rowan, EC, Coon, TA, Butler, PL, Gakhar, L, Mathur, SN, Sieren, JC, Mallampalli, RK, ....et all. Dynamic regulation of cardiolipin by the lipid pump, ATP8b1 determines the severity of lung injury in experimental pneumonia. Nature Med. 2010; Oct;16(10): 1120-7.
Sponsored Research/Activities
Title: F box-Induced Acute Lung Injury and Parkin
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL096376
Start Year: 2016
End Year: 2020
Title: Novel F Box Immunomodulator for Lung Allograft Rejection
Role: Principal Investigator
Funding Agency: Harrington Discovery Institute
Start Year: 2016
End Year: 2017
Title: Regulation of F Box Proteins in Acute Lung Injury
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL081784
Start Year: 2014
End Year: 2018
Title: Cardiolipin as a Novel Mediator of Acute Lung Injury - Project 1
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: P01 HL114453
Start Year: 2014
End Year: 2018
Title: Mechanisms of Lung Homeostatis by F box Proteins
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL097376
Start Year: 2014
End Year: 2018
Title: Novel F Box Anti-Inflammatories for COPD
Role: Principal Investigator
Funding Agency: Flight Attendants Medical Research Institute
Start Year: 2014
End Year: 2017
Title: A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: UH2 HL123520
Start Year: 2014
End Year: 2017
Title: Translational Training Program in Pulmonary Biology and Medicine
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: T32 HL007563
Start Year: 2013
End Year: 2018
Title: Targeting a Ubiquitin E3 Ligase Subunit in Acute Lung Injury
Role: Principal Investigator
Funding Agency: Bayer Corporation
Start Year: 2013
End Year: 2015
Title: Septic Lung Injury and Surfactant
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL098174
Start Year: 2010
End Year: 2017
Title: Cardiolipin Induced Lung Injury and FIC1
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL096376
Start Year: 2010
End Year: 2016
Title: Mechanisms of Lung Phospholipid Homeostasis
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL097376
Start Year: 2009
End Year: 2014
Title: TNFa Regulation of a Surfactant Enzyme in Sepsis-Induced Lung Injury
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL081784
Start Year: 2009
End Year: 2013
Title: Adenoviral Induced Acute Lung Injury and Surfactant
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL068135
Start Year: 2009
End Year: 2013
Title: Signaling Mechanisms by Which Mitochondria Regulates Fibrosis in the Lung
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL131789
Start Year: 2016
End Year: 2020
Title: Epigenetic Regulation in Acute Lung Injury
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL125435
Start Year: 2015
End Year: 2019
Title: Regulation of Innate Immunity by F-Box Proteins
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL116472
Start Year: 2013
End Year: 2018
Title: TSPI-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL108954
Start Year: 2011
End Year: 2015
Title: University of Pittsburgh Clinical and Translational Science Institute (CRRF)
Role: Co-Investigator
Funding Agency: National Center for Advancing Translational Sciences
Grant Number: UL1 TR000005
Start Year: 2011
End Year: 2013
Notable Achievements
Harrington Scholar-Innovator, Harrington Discovery Institute, 2016
Permanent Member, NHLBI Program Project Review Committee [HLBP], 2014-19
American Thoracic Society (ATS) Recognition Award for Scientific Accomplishments, 2014
Election to the Association of American Physicians (AAP), 2011
Election to the American Society for Clinical Investigation (ASCI), 2005